Table 2. Comparison of signalments, seizure activity, MRI findings, and CSF abnormalities in the four treatment groups according to therapeutic drugs

Variable	Total (n = 23)	Group1 (n = 6)	Group2 (n = 7)	Group3 (n = 4)	Group4 (n = 6)	p-value
Signalment
Age (years)	7.07 (mean)	9.00 (10.00)	5.00 (6.00)	8.00 (6.00)	5.50 (11.00)	0.53
Female (%)	13 (56.52)	2 (33.33)	3 (42.86)	4 (100)	4 (33.33)	0.19
Male (%)	10 (43.48)	4 (66.67)	4 (57.14)	0 (0.00)	2 (33.33)
Body weight (kg)	3.28 (mean)	3.73 (1.80)	2.78 (1.34)	3.83 (3.75)	2.26 (1.14)	0.16
Seizure
Presence (%)	7 (30.43)	1 (16.67)	3 (42.86)	1 (25.00)	2 (33.33)	0.92
Absence (%)	16 (69.57)	5 (83.33)	4 (57.14)	3 (75.00)	4 (66.67)
Location
Brainstem & multifocal (%)	10 (43.48)	1 (16.67)	4 (57.14)	3 (75.00)	2 (33.33)	0.32
Forebrain (%)	13 (56.51)	5 (83.33)	3 (42.86)	1 (25.00)	4 (66.67)
MRI findings
Number of abnormal MRI feature per each dog [% (IQR)]	36 (mean)	1 (1)	1 (1)	2 (3)	2.52 (2)	0.35
Lesion volume (cm3 [IQR], %)	3.82 (mean)	0.32 (1.90)	4.14 (7.86)	6.82 (2.64)	1.89 (1.41)	0.021)
CSF analysisTNCC (WBC/mm3)
Normal (%)	10 (43.48)	4 (66.67)	1 (14.29)	3 (75.00)	2 (33.33)	0.42
Abnormal (%)	10 (43.48)	2 (33.33)	4 (57.14)	1 (25.00)	3 (50.00)
Total protein (g/L)
Normal (%)	6 (26.09)	4 (66.67)	0 (0.00)	2 (50.00)	0 (0.00)	0.031)
Abnormal (%)	14 (60.87)	2 (33.33)	5 (71.43)	2 (50.00)	5 (83.33)

p<0.05.
MRI, magnetic resonance imaging; IQR, interquartile ranges; CSF, cerebrospinal fluid; TNCC, total nucleated cell count; WBC, white blood cell counts.